Home > PJ (current issue) > News / News Centre | Search

PJ Online homeThe Pharmaceutical Journal
Vol 273 No 7318 p411
25 September 2004

This article
Reprint   Photocopy

  Acrobat Reader


News summary


Industry wants to give information to patients direct

The pharmaceutical industry wants to target patients direct with more information about their drugs.

The Association of the British Pharmaceutical Industry believes the information that drug companies are allowed to include in patient information leaflets is too restrictive and it wants the opportunity to offer patients more advice about their medicines.

The idea was put forward last week when the ABPI was giving its evidence to the House of Commons Health Select Committee inquiry into the influence of the pharmaceutical industry.

An ABPI spokesman told The Journal: “It’s illegal for drug companies to communicate anything direct to patients — the patient information leaflet is just about it. If a patient phones the drug company and asks a question about their medicines, we may well know the answer, but we are not allowed to tell them and must refer them to their GP. We have long felt that this system is archaic.”

The ABPI would like to offer internet-based medicines information, along the lines of the service offered by drug companies to patients in America.

The spokesman denied that the service would be little more than advertising. He said: “This isn’t about advertising the drugs — but I agree there would have to be a fine line drawn somehow that defines it. We aren’t pressing for the sort of things you get in America where you get TV and journal advertisements advertising drugs.”

The ABPI called on the Government to take steps to increase pharmaceutical research and development by boosting the number of qualified scientists in the UK and halting the attacks on the industry by animal rights extremists. It should also reduce the cost and timescale of pharmaceutical research in the UK.

Director general of the ABPI, Richard Barker, said: “While there has been a long and fruitful partnership between the industry and the NHS and other stakeholders, no system is perfect.”

The next public hearing in the inquiry is planned for 14 October.

Back to Top


©The Pharmaceutical Journal